Nyxoah SA (NASDAQ:NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company has completed all 115 implants in its DREAM U.S. pivotal study, submitted the first module in the modular PMA submission and implanted the first patient in the ACCCESS U.S. pivotal study.
Invesco Q4 EPS $0.39 Beats $0.36 Estimate
Invesco (NYSE:IVZ) reported quarterly earnings of $0.39 per share which beat the analyst consensus estimate of $0.36 by 8.33 percent. This is a 54.65 percent decrease over earnings of $0.86 per share from the same period
